Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bower, J. H.
Right arrow Articles by Rocca, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bower, J. H.
Right arrow Articles by Rocca, W. A.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Parkinson's disease/Parkinsonism
Right arrow All epidemiology
Right arrow Case control studies
NEUROLOGY 2006;67:494-496
© 2006 American Academy of Neurology
Brief Communications

Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study

J. H. Bower, MD, D. M. Maraganore, MD, B. J. Peterson, BS, J. E. Ahlskog, PhD, MD and W. A. Rocca, MD, MPH

From the Department of Neurology (J.H.B., D.M.M., J.E.A., W.A.R.), Division of Biostatistics, Department of Health Sciences Research (B.J.P.), and Division of Epidemiology, Department of Health Sciences Research (W.A.R.), Mayo Clinic College of Medicine, Rochester, MN.

Address correspondence and reprint requests to Dr. James Bower, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905; e-mail: bower.james{at}mayo.edu).

The authors studied the association of markers of inflammation with the later development of Parkinson disease (PD) using a case-control design (196 cases and 196 matched controls). The frequency of diseases of immediate-type hypersensitivity was significantly higher in cases than controls. In addition, cases used anti-inflammatory agents less frequently than controls (nonsignificant trend). The results may support the hypothesis that there is an inflammatory component in the pathogenesis of PD.

Supported by NIH grants R01 NS33978 and R01 ES10751 and made possible by the Rochester Epidemiology Project (grant R01 AR30582).

Disclosure: The authors report no conflicts of interest.

Received September 16, 2005. Accepted in final form March 31, 2006.




This article has been cited by other articles:


Home page
 NeurologyHome page
A. D. Wahner, J. M. Bronstein, Y. M. Bordelon, and B. Ritz
Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease
Neurology, November 6, 2007; 69(19): 1836 - 1842.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
D. B. Hancock, E. R. Martin, J. M. Stajich, R. Jewett, M. A. Stacy, B. L. Scott, J. M. Vance, and W. K. Scott
Smoking, Caffeine, and Nonsteroidal Anti-inflammatory Drugs in Families With Parkinson Disease
Arch Neurol, April 1, 2007; 64(4): 576 - 580.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.